Amélioration des signes et symptômes chez les patients atteints de spondyloathrite axiale non radiographique traités par le bimékizumab : résultats à 24 semaines d’une étude de phase III

Autor: M. Breban, A. Deodhar, D. Van Der Heijde, L.S. Gensler, H. Xu, K. Gaffney, H. Dobashi, W. Maksymowych, M. Rudwaleit, M. Magrey, D. Elewaut, M. Oortgiesen, C. Fleurinck, N. De Peyrecave, A.M. Ellis, T. Vaux, J. Sheperd-Smith, X. Baraliakos

Publikováno v: Revue du Rhumatisme. 89:A138-A139

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40b33cac5f5d74713cbf76a9befd6765
https://doi.org/10.1016/j.rhum.2022.10.203

Le bimékizumab améliore les principaux symptômes rapportés par les patients atteints de spondylarthrite axiale, notamment les douleurs rachidiennes et la fatigue : résultats de deux études de phase III

Autor: M. Dougados, P.J. Mease, A. Deodhar, M. Dubreuil, M. Magrey, H. Marzo-Ortega, M. Rudwaleit, C. De La Loge, A.M. Ellis, C. Fleurinck, M. Oortgiesen, V. Taieb, L.S. Gensler

Publikováno v: Revue du Rhumatisme. 89:A239-A240

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbf706dca24bbec18640c4e01fc8f1d6
https://doi.org/10.1016/j.rhum.2022.10.376

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Autor: Maxime Dougados, Atul Deodhar, Désirée van der Heijde, Jason Coarse, Dominique Baeten, Nadine Goldammer, M. Oortgiesen, Denis Poddubnyy, Mary Katherine Farmer, Alan Kivitz, Lianne S. Gensler, Xenofon Baraliakos

Publikováno v: Annals of the Rheumatic Diseases, 79(5), 595-604. BMJ PUBLISHING GROUP
Annals of the rheumatic diseases, 79(5), 595-604. BMJ Publishing Group
Annals of the Rheumatic Diseases

ObjectivesBimekizumab selectively neutralises both interleukin (IL)-17A and IL-17F. We report efficacy and safety in a phase IIb dose-ranging study in patients with active ankylosing spondylitis (AS).MethodsAdults with AS (fulfilling modified New Yor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7aa9528bb371f3d6e2d817c723d79f6
https://doi.org/10.1136/annrheumdis-2020-216980

POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION

Autor: V. Navarro-Compán, M. Rudwaleit, N. De Peyrecave, C. Fleurinck, M. Oortgiesen, V. Taieb, X. Baraliakos

Publikováno v: Annals of the Rheumatic Diseases. 81:771-772

BackgroundBimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL 17A, has demonstrated significant and rapid efficacy in patients (pts) with active ankylosing spondylitis (AS) treated for up to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed6fa632ea31c01f5b7b13f4dbe5de60
https://doi.org/10.1136/annrheumdis-2022-eular.2138

Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante : résultats à 3 ans d’une étude de phase IIb

Autor: X. Baraliakos, D. van der Heijde, Maxime Dougados, Lianne S. Gensler, T. Vaux, M. Oortgiesen, Denis Poddubnyy, N. De Peyrecave, Alan Kivitz, C. Fleurinck, A. Deodhar

Publikováno v: Revue du Rhumatisme. 88:A261-A262

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3cfa94dd24f9bf2725b0d564b2a88c7f
https://doi.org/10.1016/j.rhum.2021.10.441